Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor
Ontology highlight
ABSTRACT: RATIONALE: Studying samples of blood and urine in the laboratory from patients with cancer receiving bevacizumab may help doctors learn more about changes that occur in DNA and identify biomarkers related to high blood pressure.
PURPOSE: This phase I trial is studying potential biomarkers for bevacizumab-induced high blood pressure in patients with malignant solid tumors, including breast cancer, colorectal cancer, non-small cell lung cancer, head and neck cancer, ovarian cancer, fallopian tube cancer, or primary peritoneal carcinoma.
DISEASE(S): Lung Cancer,Colorectal Cancer,Fallopian Tube Cancer,Head And Neck Neoplasms,Breast Neoplasms,Lung Neoplasms,Breast Cancer,Cardiovascular Complications,Unspecified Adult Solid Tumor, Protocol Specific,Ovarian Cancer,Fallopian Tube Neoplasms,Peritoneal Cavity Cancer,Head And Neck Cancer
PROVIDER: 2087045 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA